Biotricity, Inc.
BTCY · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $14 | $12 | $10 | $8 |
| % Growth | 14.3% | 25.2% | 26% | – |
| Cost of Goods Sold | $3 | $4 | $4 | $3 |
| Gross Profit | $11 | $8 | $5 | $5 |
| % Margin | 76.6% | 69.3% | 56.5% | 59.7% |
| R&D Expenses | $2 | $3 | $3 | $3 |
| G&A Expenses | $11 | $15 | $18 | $19 |
| SG&A Expenses | $11 | $15 | $18 | $19 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $13 | $17 | $21 | $21 |
| Operating Income | -$2 | -$9 | -$15 | -$17 |
| % Margin | -17.8% | -73.2% | -159.9% | -218.8% |
| Other Income/Exp. Net | -$6 | -$5 | -$3 | -$12 |
| Pre-Tax Income | -$8 | -$14 | -$19 | -$29 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$14 | -$19 | -$29 |
| % Margin | -61.1% | -116.8% | -193.6% | -380.8% |
| EPS | -0.55 | -1.66 | -2.26 | -3.99 |
| % Growth | 66.9% | 26.5% | 43.4% | – |
| EPS Diluted | -0.55 | -1.66 | -2.26 | -3.99 |
| Weighted Avg Shares Out | 22 | 9 | 9 | 8 |
| Weighted Avg Shares Out Dil | 22 | 9 | 9 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $5 | $5 | $3 | $11 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$9 | -$16 | -$19 |
| % Margin | -23.3% | -73.7% | -166.7% | -242.6% |